[ NATIONAL · CA ]
A single federal health authority licensing establishments and inspecting against its own GMP guide.
SPEQ synthesis for orientation. It does not determine what applies to a specific product, and an adopted version can move without this page moving with it. Confirm the instrument in force with the authority before relying on it.
NORTH AMERICA
The Food and Drugs Act, and the Food and Drug Regulations (C.R.C., c. 870) made under it. Within Part C of those Regulations the licensing regime and the manufacturing standard sit in separate divisions: Division 1A carries drug establishment licences, and Divisions 2 to 4 carry good manufacturing practices. An establishment licence application must be supported by evidence — a certificate from a Canadian inspector, or other documentation — that the buildings, equipment, practices and procedures of the fabricator, packager/labeller and tester meet the applicable requirements of Divisions 2 to 4.
Through a licence, and inspection against it. Health Canada issues a Drug Establishment Licence naming each regulated activity — fabricating, packaging/labelling, testing, importing, distributing, wholesaling — and each site, so adding an activity or a site is an amendment rather than a notification. The agency publishes GUI-0001, its good manufacturing practices guide for drug products, which interprets the Division 2 requirements. GUI-0001 is an administrative document and does not itself have the force of law: the Regulations create the obligation, and the guide explains how Health Canada expects it to be met.
WHAT TRANSFERS
More than in most markets, and still not the licence. The Regulations contemplate evidence other than a Canadian inspection to support an establishment licence, which is what lets a foreign site be assessed on documentation rather than on a visit — and Canada’s participation in ICH and in PIC/S is what makes that documentation legible. What does not transfer is the permission itself. The establishment licence is Canadian, held for named activities at named sites, and no foreign certificate or inspection outcome substitutes for holding one.
A Drug Establishment Licence authorises specific regulated activities at specific buildings. Fabricating, packaging/labelling, testing, importing, distributing and wholesaling are separate authorisations, and doing one you do not hold is an unlicensed activity rather than a documentation gap.
Division 1A is about permission — who may do what, where, and on what evidence. Divisions 2 to 4 are the manufacturing standard that evidence has to demonstrate. Teams that read only the GMP divisions have the standard without the mechanism that enforces it.
It is the document Health Canada inspects against and the one to reconcile site procedures with, but the enforceable text is the Regulations. Where the distinction matters — an observation, a submission, a dispute — cite the Regulation and use the guide to explain the expectation.
An importer’s licence carries responsibility for the foreign sites in its supply chain. The evidence supporting those sites is part of the importer’s licence file, which makes the importer, not the manufacturer, the party that feels a documentation gap first.
The Food and Drugs Act and the Food and Drug Regulations (C.R.C., c. 870) made under it. In Part C, Division 1A covers drug establishment licences and Divisions 2 to 4 cover good manufacturing practices.
No. GUI-0001 is the good manufacturing practices guide for drug products and it interprets the Division 2 requirements, but it is an administrative document without the force of law. The Regulations establish the requirement; the guide explains how Health Canada expects regulated establishments to meet it.
It can support the evidence. An application must show that the buildings, equipment, practices and procedures of the fabricator, packager/labeller and tester meet the applicable requirements of Divisions 2 to 4, and that evidence may be a certificate from a Canadian inspector or other documentation. Canada’s participation in ICH and PIC/S is what makes evidence from those systems legible — but the licence itself is Canadian and must be held.
ADOPTED, AT A PINNED VERSION
SPEQ has not decoded a pinned adoption edge here yet. That is a gap in this catalog, not a finding about Canada: requirements still arrive through the authorities below, and the edition in force is theirs to state.
Participation changes which evidence transfers, and which edition of a harmonized guide the local instrument is likely to pin.